Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
BRCA1/2
Bilateral risk-reducing mastectomy
Prevention
Surveillance
Survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
27
05
2019
accepted:
02
07
2019
pubmed:
16
7
2019
medline:
12
2
2020
entrez:
15
7
2019
Statut:
ppublish
Résumé
In healthy BRCA1/2 mutation carriers, bilateral risk-reducing mastectomy (BRRM) strongly reduces the risk of developing breast cancer (BC); however, no clear survival benefit of BRRM over BC surveillance has been reported yet. In this Dutch multicenter cohort study, we used multivariable Cox models with BRRM as a time-dependent covariable to estimate the associations between BRRM and the overall and BC-specific mortality rates, separately for BRCA1 and BRCA2 mutation carriers. During a mean follow-up of 10.3 years, 722 out of 1712 BRCA1 (42%) and 406 out of 1145 BRCA2 (35%) mutation carriers underwent BRRM. For BRCA1 mutation carriers, we observed 52 deaths (20 from BC) in the surveillance group, and 10 deaths (one from BC) after BRRM. The hazard ratios were 0.40 (95% CI 0.20-0.90) for overall mortality and 0.06 (95% CI 0.01-0.46) for BC-specific mortality. BC-specific survival at age 65 was 93% for surveillance and 99.7% for BRRM. For BRCA2 mutation carriers, we observed 29 deaths (7 from BC) in the surveillance group, and 4 deaths (no BC) after BRRM. The hazard ratio for overall mortality was 0.45 (95% CI 0.15-1.36). BC-specific survival at age 65 was 98% for surveillance and 100% for BRRM. BRRM was associated with lower mortality than surveillance for BRCA1 mutation carriers, but for BRCA2 mutation carriers, BRRM may lead to similar BC-specific survival as surveillance. Our findings support a more individualized counseling based on BRCA mutation type.
Sections du résumé
BACKGROUND
BACKGROUND
In healthy BRCA1/2 mutation carriers, bilateral risk-reducing mastectomy (BRRM) strongly reduces the risk of developing breast cancer (BC); however, no clear survival benefit of BRRM over BC surveillance has been reported yet.
METHODS
METHODS
In this Dutch multicenter cohort study, we used multivariable Cox models with BRRM as a time-dependent covariable to estimate the associations between BRRM and the overall and BC-specific mortality rates, separately for BRCA1 and BRCA2 mutation carriers.
RESULTS
RESULTS
During a mean follow-up of 10.3 years, 722 out of 1712 BRCA1 (42%) and 406 out of 1145 BRCA2 (35%) mutation carriers underwent BRRM. For BRCA1 mutation carriers, we observed 52 deaths (20 from BC) in the surveillance group, and 10 deaths (one from BC) after BRRM. The hazard ratios were 0.40 (95% CI 0.20-0.90) for overall mortality and 0.06 (95% CI 0.01-0.46) for BC-specific mortality. BC-specific survival at age 65 was 93% for surveillance and 99.7% for BRRM. For BRCA2 mutation carriers, we observed 29 deaths (7 from BC) in the surveillance group, and 4 deaths (no BC) after BRRM. The hazard ratio for overall mortality was 0.45 (95% CI 0.15-1.36). BC-specific survival at age 65 was 98% for surveillance and 100% for BRRM.
CONCLUSION
CONCLUSIONS
BRRM was associated with lower mortality than surveillance for BRCA1 mutation carriers, but for BRCA2 mutation carriers, BRRM may lead to similar BC-specific survival as surveillance. Our findings support a more individualized counseling based on BRCA mutation type.
Identifiants
pubmed: 31302855
doi: 10.1007/s10549-019-05345-2
pii: 10.1007/s10549-019-05345-2
pmc: PMC6745043
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
723-733Subventions
Organisme : Dutch Pink Ribbon foundation
ID : 2016-209
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
N Engl J Med. 2001 Jul 19;345(3):159-64
pubmed: 11463009
J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7
pubmed: 11698567
J Clin Oncol. 2002 May 1;20(9):2310-8
pubmed: 11981002
J Clin Oncol. 2002 May 15;20(10):2520-9
pubmed: 12011131
Int J Methods Psychiatr Res. 2002;11(2):68-74
pubmed: 12459796
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
J Natl Cancer Inst. 2003 Jul 2;95(13):941-7
pubmed: 12837830
J Clin Oncol. 2004 Mar 15;22(6):1055-62
pubmed: 14981104
Eur J Cancer. 2007 Mar;43(5):867-76
pubmed: 17307353
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
Breast Cancer Res Treat. 2010 Feb;120(1):235-44
pubmed: 19680614
J Clin Oncol. 2010 Jan 10;28(2):222-31
pubmed: 19996031
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
Clin Genet. 2011 May;79(5):431-7
pubmed: 21199491
J Clin Oncol. 2012 Feb 10;30(5):497-506
pubmed: 22231042
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77
pubmed: 22556274
Ann Oncol. 2013 Aug;24(8):2029-35
pubmed: 23576707
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22
pubmed: 23628597
Breast Cancer Res Treat. 2013 Dec;142(3):611-8
pubmed: 24249359
J Med Genet. 2014 Feb;51(2):98-107
pubmed: 24285858
J Natl Cancer Inst. 2015 Mar 18;107(5):null
pubmed: 25788320
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Breast Cancer Res Treat. 2018 Jan;167(1):263-267
pubmed: 28914396
Cochrane Database Syst Rev. 2018 Apr 05;4:CD002748
pubmed: 29620792
Avicenna J Med. 2018 Jul-Sep;8(3):67-77
pubmed: 30090744
Br J Cancer. 2019 Jul;121(1):15-21
pubmed: 30971774
Stat Med. 1984 Jan-Mar;3(1):35-44
pubmed: 6729287